Related Experiment Video
Updated: Jun 26, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
2-methoxyestradiol as a potential cytostatic drug in gliomas?
1Institute of Neuropathology, Otto-von-Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany. Elmar.kirches@medizin.uni-magdeburg.de
Abstract:
Gliomas of astrocytic origin show only a limited chemotherapy response. Chemoresistance is most pronounced in glioblastoma multiforme, the most common and most malignant glioma, with median survival times not much longer than one year. Failure of chemotherapy partly relies on protective mechanisms against the commonly used DNA alkylating agents, but also on the constitutive activation of the pro-survival PI3K-Akt pathway in glioma cells, which inhibits apoptosis. Therefore, new drugs with an alternative mechanism, independent of DNA alkylation, are required. The microtubule targeting drug 2-methoxyestradiol (2-ME) efficiently induces mitotic arrest, apoptosis, but also autophagic cell death in glioma cells in vitro. Moreover, it may be able to inhibit vascularization of the highly vascular gliobastomas, because the drug influences blood vessel sprouting via a HIF-1-dependent mechanism. Although high doses of i.p. injected 2-ME were recently shown to be effective in an orthothopic rat glioma model, clinical phase I/II trials revealed low oral bioavailability. One of the most exciting future perspectives will be the currently ongoing development of improved 2-ME analogs. Compounds, sulphamoylated at positions 3 and 17, combine sufficient toxicity against tumor cells with resistance against metabolic degradation and sufficient plasma levels in experimental animals. They were found to be superior in some animal models of tumor growth and vascularization, following oral application.
Insights
New glioma treatments are needed due to chemotherapy resistance. 2-methoxyestradiol (2-ME) shows promise by targeting microtubules and inhibiting tumor vascularization, with improved analogs offering better oral bioavailability for future glioblastoma therapy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Astrocytic gliomas, particularly glioblastoma multiforme, exhibit limited response to chemotherapy.
- Chemoresistance is linked to DNA alkylating agent protection and PI3K-Akt pathway activation, inhibiting apoptosis.
- Novel therapeutic strategies independent of DNA alkylation are crucial for improving glioma patient outcomes.
Purpose of the Study:
- To evaluate 2-methoxyestradiol (2-ME) as a novel therapeutic agent for gliomas.
- To investigate 2-ME's mechanisms of action, including mitotic arrest, apoptosis, and autophagic cell death induction.
- To explore 2-ME's potential in inhibiting glioblastoma vascularization and assess the efficacy of improved analogs.
Main Methods:
- In vitro studies on glioma cells to assess 2-ME's cytotoxic effects and cell death induction.
- Investigation of 2-ME's impact on tumor vascularization via HIF-1 dependent mechanisms.
- Evaluation of 2-ME and its novel analogs in orthotopic rat glioma models and clinical trials.
Main Results:
- 2-methoxyestradiol (2-ME) effectively induces mitotic arrest, apoptosis, and autophagic cell death in glioma cells in vitro.
- 2-ME demonstrates potential to inhibit glioblastoma vascularization through a HIF-1 dependent mechanism.
- While systemic 2-ME showed efficacy in a rat model, clinical trials indicated low oral bioavailability, prompting development of improved analogs.
Conclusions:
- 2-methoxyestradiol (2-ME) presents a promising alternative therapeutic strategy for gliomas, acting via microtubule disruption and anti-angiogenic effects.
- Novel sulphamoylated 2-ME analogs exhibit enhanced tumor cell toxicity, metabolic stability, and oral bioavailability in preclinical models.
- These improved 2-ME analogs represent a significant advancement for oral glioblastoma treatment, offering potential for better patient outcomes.
